Explore more Norwegian companies →
COMPANY CARD COMPANY
ALGIPHARMA AS
Research and experimental development on natural sciences and engineering
-23 016,6 % EBIT margin
FINANCIALS
Financial statements and key figures
Company financial statements
Amount in NOK
| Financial statement item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Currency | NOK | NOK | NOK | NOK | NOK |
| Operating revenue | 29 219 | 5 738 | 85 940 | 40,000 | 65,000 |
| Operating profit | -6 725 210 | -6 858 426 | -5 843 676 | -7,945,000 | -6,637,000 |
| Net income | -8 676 949 | -8 962 504 | -9 715 740 | -7,073,000 | -10,658,000 |
| Equity | 197 468 543 | 176 145 487 | 128 587 961 | 27,888,000 | 34,962,000 |
| Total assets | 232 824 118 | 207 325 830 | 188 878 585 | 173,351,000 | 155,526,000 |
| Total liabilities | 35 355 574 | 31 180 343 | 60 290 624 | 145,462,000 | 120,565,000 |
| EBIT margin | -23 016,6 % | -119 526,4 % | -6 799,7 % | -19 862,5 % | -10 210,8 % |
Historical company accounts in NOK. The source identifies the year. A dash indicates an unavailable amount.
Indicators: equity / assets and EBIT / operating revenue. Midline is 0%, scale −100% to +100%. Not a credit assessment.
Show trend in NOK
Click the year markers for exact amounts. Missing years create gaps. The financial statement table above shows all amounts.
Click the year markers for exact amounts. Missing years create gaps. The financial statement table above shows all amounts.
Sources and conversion basis
Companies and corporate groups are kept separate. The same historical annual exchange rate is used for income statement and balance sheet figures. Missing values are shown as “—”. Actual zero values are retained.
- 2025 · NOK · original-NOK · source version 54f716b32e69
- 2024 · NOK · original-NOK · source version 3faf31100829
- 2023 · NOK · original-NOK · source version 817dcc96f9da
Expand for more financial statement items. We show items with information in at least one year. “—” means a value is missing for that year.
Income statement14 entries with information
| Financial statement item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating revenue | |||||
| Total sales revenue | 29 219 | 5 738 | 85 940 | 40,000 | 65,000 |
| Total operating revenue | 29 219 | 5 738 | 85 940 | 40,000 | 65,000 |
| Operating expenses | |||||
| Wage costs | 1 185 141 | -230 253 | -561 056 | 2,237,000 | 2,561,000 |
| Total operating expenses | 6 754 429 | 6 864 163 | 5 929 616 | — | — |
| Operating profit | |||||
| Operating income (EBIT) | -6 725 210 | -6 858 426 | -5 843 676 | -7,945,000 | -6,637,000 |
| Financial income | |||||
| Total finance income | 1 603 144 | 1 714 483 | 1 868 780 | 2,223,000 | 79,000 |
| Financial expenses | |||||
| Other interest expense | 1 257 233 | 982 918 | 1 651 838 | 1,070,000 | 970,000 |
| Interest expense to company in same group | 928 766 | 2 360 102 | 3 551 576 | — | — |
| Total finance costs | 3 554 883 | 3 818 561 | 5 856 614 | 1,352,000 | 4,099,000 |
| Net finance result | -1 951 739 | -2 104 079 | -3 987 833 | — | — |
| Results and tax | |||||
| Income before tax | -8 676 949 | -8 962 504 | -9 831 509 | -7,073,000 | -10,658,000 |
| Tax expense on ordinary income | 0 | 0 | -115 769 | — | — |
| Net income | -8 676 949 | -8 962 504 | -9 715 740 | -7,073,000 | -10,658,000 |
| Total comprehensive income | -8 676 949 | -8 962 504 | -9 715 740 | — | — |
Balance sheet12 entries with information
| Financial statement item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Intangible assets | |||||
| Goodwill | 0 | 0 | — | — | — |
| Financial fixed assets | |||||
| Total non-current assets | 225 097 166 | 201 536 517 | 181 567 841 | 168,449,000 | 149,488,000 |
| Current assets | |||||
| Total receivables | 6 046 948 | 4 617 773 | 6 326 210 | 4,037,000 | 5,073,000 |
| Total cash and cash equivalents | 1 680 004 | 1 171 540 | 984 533 | 865,000 | 965,000 |
| Total current assets | 7 726 952 | 5 789 313 | 7 310 744 | 4,902,000 | 6,038,000 |
| Total assets | 232 824 118 | 207 325 830 | 188 878 585 | 173,351,000 | 155,526,000 |
| Equity | |||||
| Total paid-in equity | 197 468 543 | 176 145 487 | 128 587 961 | 27,888,000 | 34,962,000 |
| Total equity | 197 468 543 | 176 145 487 | 128 587 961 | 27,888,000 | 34,962,000 |
| Provisions and long-term liabilities | |||||
| Total long-term liabilities | 20 184 649 | 14 823 888 | 47 665 861 | — | — |
| Current liabilities | |||||
| Total current liabilities | 15 170 925 | 16 356 455 | 12 624 763 | 17,695,000 | 8,305,000 |
| Total liabilities | 35 355 574 | 31 180 343 | 60 290 624 | 145,462,000 | 120,565,000 |
| Total | |||||
| Total equity and liabilities | 232 824 118 | 207 325 830 | 188 878 585 | 173,351,000 | 155,526,000 |
Executive salaryUnavailable
No information in the available financial statement data.
Some amounts for 2021 and 2022 come from a financial statements archive and are rounded to the nearest NOK 1,000. The source does not specify reporting dates or whether these figures cover the company or a group.
REGISTRY INFORMATION
Company at a glance
- Industry
- 72.100 · Research and experimental development on natural sciences and engineering Industry classification: Statistics Norway · CC BY 4.0
- Registered address
- Industriveien 33, 1337 SANDVIKA
- Founded
- 25.05.1992
- Entity type
- Main entity
ADDRESS AND PROPERTY
Property information
Industriveien 33, 1337 SANDVIKA
Companies at the same address
Available company cards
About the address match
Same registered street address, postal code, and municipality. This does not document ownership, tenancy, or who uses the building. The address match does not identify a specific unit or dwelling. Open information does not show titleholders, sale date, plot area, or a complete building overview.
REGISTERED ROLES
The people and companies behind it.
| Name | Role | Source date |
|---|---|---|
| Yngvar Peter BergBorn 1962 | Board member | 14.11.2026 |
| Yngvar Peter BergBorn 1962 | General manager | 14.11.2026 |
| Diderik Børsting SchnitlerBorn 1946 | Board member | 14.11.2026 |
| CEDRA NORGE ASView role record | Auditor | 14.11.2026 |
| Arne DessenBorn 1959 | Chair of the board | 14.11.2026 |
Source: Brønnøysund Register Centre. A registered role is not documentation of direct contact information.
YEAR-DATED OWNERSHIP
Reported shareholders.
As of 31 December 2025 · 1 of 1 available ownership entries
| Shareholder | Share / share class | Source date |
|---|---|---|
| ALGIPHARMA HOLDING ASView ownership entryView share entries → | 100,00 % · Ordinary shares | 31.12.2025 |
- ALGIPHARMA HOLDING ASOrdinary shares100,00 %
Fixed scale 0–100%. Shares are not normalized. Any unfilled portion is outside the displayed total.
Source: Skatteetaten. Ownership share is a share of the number of shares, not necessarily voting rights or control. Person names refer to separate source records. Similar names are not automatically the same person.
Previously reported ownership entries (2)
- 2024 · ALGIPHARMA HOLDING AS · 100,00 %
- 2023 · ALGIPHARMA HOLDING AS · 100,00 %
YEAR-DATED OWNERSHIP
Company share entries
The company’s own investments in other businesses. Shareholders who own the company are shown under Ownership.
Source and scope
Skatteetaten / Aksjonærregisteret. Every level uses the same source year and source set. Further links follow Norwegian business registration numbers; foreign identifiers are not linked automatically. Calculated share is the product of reported share count / total shares at each level, not voting rights, control, or today’s shareholder register. Partial source coverage is stated at the relevant level; unresolved calculation basis is shown without a percentage.
Up to 500 source records examined; the view may be limited. Missing matches do not prove that ownership is absent.
YEAR-DATED OWNERSHIP
Indirect ownership
Explore documented ownership paths through companies. Each path and share class is shown separately; shares are not added together.
Source and scope
Skatteetaten / Aksjonærregisteret. Every level uses the same source year and source set. Further links follow Norwegian business registration numbers; foreign identifiers are not linked automatically. Calculated share is the product of reported share count / total shares at each level, not voting rights, control, or today’s shareholder register. Partial source coverage is stated at the relevant level; unresolved calculation basis is shown without a percentage.
Up to four ownership levels, 32 company lookups, and 250 chains are examined within a short time budget. This is a limited selection, not a ranking of the largest 250. Cycles are stopped. Missing matches do not prove that ownership is absent.
CONNECTIONS
Explore the ownership structure.
Directly reported ownership entries are shown first. Open the map to explore further.
Direct ownership entries without an interactive map
As of 31 December 2025 · 1 of 1 available ownership entries
| Shareholder | Share / share class | Source date |
|---|---|---|
| ALGIPHARMA HOLDING ASView ownership entryView share entries → | 100,00 % · Ordinary shares | 31.12.2025 |
Source: Skatteetaten / Aksjonærregisteret. Year-dated share ownership is not necessarily today’s voting rights or corporate control.
Open interactive map for direct ownership entries
CONNECTIONS
Explore the ownership structure.
See owners and open further company levels, using the same year throughout the tree.
Click a company to open owners. Select i for details.